Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AMED CoROCO:7575 56 EV-to-EBIT is 12.01 as of Sep. 10, 2026, which is 28% below its 10-year median of 16.79. GuruFocus rates ROCO:7575 with a GF Score™ of 56/100 and a GF Value™ of NT$63.31 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 475 Medical Devices & Instruments companies, AMED Co ranks better than 68.63% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AMED Co's Enterprise Value is NT$815.7 Mil.
AMED Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$67.9 Mil. Therefore, AMED Co's EV-to-EBIT for today is 12.01.
The historical rank and industry rank for AMED Co's EV-to-EBIT or its related term are showing as below:
ROCO:7575'
s EV-to-EBIT Range Over the Past 10 Years
Min: 10.61 Med: 16.79 Max: 26.37
Current: 12.01
During the past 7 years, the highest EV-to-EBIT of AMED Co was 26.37. The lowest was 10.61. And the median was 16.79.
ROCO:7575's EV-to-EBIT is ranked better than 68.63% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 18.4
vs ROCO:7575: 12.01
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AMED Co's Enterprise Value for the quarter that ended in Dec. 2025 was NT$1,339.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AMED Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$67.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMED Co EV-to-EBIT Related Terms
AMED Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AMED Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7575 vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, AMED Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AMED Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AMED Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AMED Co's EV-to-EBIT falls into.
AMED Co's current Enterprise Value is NT$815.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AMED Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$67.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMED Co (ROCO:7575) has a EV-to-EBIT of 12.01 as of Sep. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AMED Co and its competitors. This is 28% below median its historical median of 16.79. Over the past decade, AMED Co's EV-to-EBIT has ranged from 10.61 to 26.37. According to the industry distribution chart, AMED Co ranks #149 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 31.4%.
Is AMED Co's EV-to-EBIT too high?
AMED Co's current EV-to-EBIT of 12.01 is 28% below median its 10-year median of 16.79. Over the past 10 years, this metric has ranged from a low of 10.61 to a high of 26.37. The Medical Devices & Instruments industry median EV-to-EBIT is 18.40. AMED Co's value of 12.01 is 34.7% below this industry median. Based on the distribution chart, AMED Co ranks #149 out of 475 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, AMED Co has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AMED Co's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AMED Co ranks #149 out of 475 companies for EV-to-EBIT. This puts AMED Co in the upper half of its industry. The industry median EV-to-EBIT is 18.40. AMED Co's value of 12.01 is 34.7% below this benchmark. Historically, AMED Co's own EV-to-EBIT has ranged from 10.61 to 26.37 over the past decade. While the company's 10-year median is 16.79 vs. the industry median of 18.40, AMED Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.40, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AMED Co's current EV-to-EBIT of 12.01 is 34.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AMED Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AMED Co's current EV-to-EBIT is 12.01, which is 28% below median its own 10-year median of 16.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AMED Co stock overvalued right now?
Based on GuruFocus' analysis, AMED Co (ROCO:7575) is currently considered Possible Value Trap. The stock's GF Value™ is NT$63.31, compared to a current price of NT$11.45 — trading 81.9% below its estimated fair value. The current EV-to-EBIT is 12.01, which is 28% below median its 10-year median of 16.79 and 34.7% below the Medical Devices & Instruments industry median of 18.40. AMED Co's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AMED Co (ROCO:7575), the current EV-to-EBIT is 12.01 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AMED Co (ROCO:7575) Overvalued in 2026?
Based on GuruFocus' analysis, AMED Co stock appears to be undervalued.
The current stock price of NT$11.45 is trading 81.9% below its estimated GF Value™ of NT$63.31.
GuruFocus considers AMED Co to be Possible Value Trap.
Key valuation signals for ROCO:7575:
EV-to-EBIT: 12.01 (28% below median its 10-year median of 16.79)
GF Value™: NT$63.31 vs. price of NT$11.45 (81.9% below fair value)
Industry Position: 34.7% below the Medical Devices & Instruments median (#149 of 475)
No single metric tells the full story. See the ROCO:7575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AMED Co Ltd is fully committed to the research and development of UV photopolymerized hydrogels. It is a professional research and development and manufacturing company of wound dressing materials, providing proper wound care solutions, and marketing the product under the brand of Heli Dressing.
56GF Score
Get the complete analysis for ROCO:7575
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7575 has been successfully added to your 
